ANAB
AnaptysBio Inc
51.00$
-1.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +124.5% | +10.5% | +429.7% | +54.5% | -14.5% | -4.3% | +54.4% | -5.1% | -25.9% | +7.0% | -24.7% | |
| – | +119.1% | +8.9% | +334.1% | +71.8% | -13.0% | +5.0% | +39.7% | -19.3% | -9.0% | +6.2% | -18.9% | |
| – | +132.9% | -0.9% | +58.5% | +39.9% | +50.5% | +46.5% | +97.9% | -85.6% | -49.6% | +242.2% | +93.5% | |
| – | +132.9% | -0.9% | +384.9% | +71.9% | -12.4% | +5.2% | +39.2% | -19.5% | -11.4% | -1.4% | -19.1% | |
| – | -15.7% | +335.8% | -70.0% | -89.1% | – | – | – | +62.0% | +382.8% | +495.0% | -17.0% | |
| – | – | – | -100.0% | – | – | – | – | +0.0% | +0.0% | – | – | |
| – | -4.8% | -14.5% | +41.2% | +117.3% | +109.0% | -41.0% | +28.0% | -8.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -26.9% | +64.3% | -4.9% | +3.9% | +33.4% | -34.3% | +1,346.2% | +21.5% | +4.6% | +13.4% | -20.8% | |
| – | -36.9% | -22.6% | +146.8% | +55.0% | +35.3% | -32.9% | -18.8% | +61.8% | +43.7% | +21.3% | -15.0% | |
| – | -83.7% | -95.2% | +689,100.0% | +10.7% | -70.6% | -84.8% | +340.1% | +8.8% | +8.6% | +8.3% | +8.1% | |
| – | +266.5% | +49.8% | +2.0% | +134.3% | +198.3% | -74.0% | -58.7% | +59.9% | +68.8% | -14.8% | -3.3% | |
| – | +2.3% | +181.6% | -45.3% | -91.7% | – | – | – | – | – | – | – | |
| – | +606.4% | -7.2% | +683.3% | +58.1% | -16.7% | -2.0% | -10.2% | -26.5% | -66.4% | -19.6% | -47.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.8% | +3.4% | +650.2% | +24.7% | +9.7% | +0.9% | +0.5% | +2.7% | -4.4% | +5.4% | +10.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.